AbbVie Revs Up The Race To Market In Uterine Fibroids

AbbVie and Neurocrine submitted an NDA to FDA for elagolix for bleeding associated with uterine fibroids, leading in what is expected to be a competitive market.

Submit; Stack of Documents on white desk and Background. - Image — AbbVie filed elagolix with FDA for bleeding associated with uterine fibroids

AbbVie Inc. and partner Neurocrine Biosciences Inc. have beat Myovant Sciences Ltd. to the US Food and Drug Administration's doorstep with a new drug application (NDA) for the first oral gonadotropin-releasing hormone (GnRH) antagonist, elagolix, for heavy menstrual bleeding associated with uterine fibroids. AbbVie announced the filing on 5 Aug., positioning the company to beat Myovant to market, as was expected.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.